the main
about the project
Medicine news
To the authors
Licensed books on medicine
<< Ahead Next >>

Hypertrophic Cardiomyopathy



Hypertrophic KMP is expressed by left ventricular and interventricular septum hypertrophy.

Clinical manifestations. More often, boys have family forms, shortness of breath, heartache, expanding the boundaries of the heart, weakening I tone at the apex, accent II tone over the pulmonary artery, changeable systolodiastolic noise on the left edge of the sternum, the development of cardiovascular failure in the left ventricular type.

Diagnostics. ECG - signs of hypertrophy of the left atrium and left ventricle; Q wave changed in II — III holes, V4, V6. EchoCG - thickening of the interventricular septum, a decrease in the volume of the left ventricle. X-ray examination of the chest - depends on the size of the heart, the displacement of the mitral valve forward.

Carnitine CMP.

Ventricular hypertrophy: KDDlzh = 65 mm, atriomegaly, EF = 0.2, mitral regurgitation of the 2nd to 3rd degrees.

Treatment.
Surgical - septal myectomy.

1. Valve replacement - two-chamber constant stimulation.

2. Conservative:

1) limitation of physical activity;

2) a diet limited in salt and water;

3) in-blockers;

4) Ca-channel blockers;

5) antiarrhythmics of other groups;

6) ACE inhibitors.

Cardiac glycosides in HCM are contraindicated.

<< Ahead Next >>
= Go to tutorial content =

Hypertrophic Cardiomyopathy

  1. Cardiomyopathy. Hypertrophic cardiomyopathy (code 142.0)
    The term "cardiomyopathy" refers to a state of unknown etiology, the most important signs of which are cardiomegaly and heart failure; this name excludes heart disease resulting from valve damage, impaired coronary blood flow, and hypertension in the large and small circulation. Etiology. Clinical and anatomical forms. Prospective
  2. Hypertrophic Cardiomyopathy
    HYPERTROPHIC CARDIOMYOPATHY is a disease of myocardium of unknown etiology, manifested by left ventricular hypertrophy (mainly interventricular septum) without dilatation. ETIOLOGY. Hypertrophic cardiomyopathy is characterized by primary hypertrophy of cardiomyoitis, which is not associated with enhanced cardiac performance. Approximately 1/3 of patients with hypertrophic cardiomyopathy observed
  3. 5. HYPERTROPHIC CARDIOMYOPATHY
    General Hypertrophic Cardiomyopathy (HCM) can be hereditary (penetrance varies) or sporadic. Synonyms: idiopathic hypertrophic subaortic stenosis, asymmetric septal hypertrophy, hypertrophic obstructive cardiomyopathy and muscular subaortic stenosis. The disease is characterized by heterogeneous LV hypertrophy with no apparent cause.
  4. Hypertrophic cardiomyopathy, dilated in children
    Protocol code: 05-057a Profile: pediatric Stage: hospital The purpose of the stage: 1. reducing the symptoms of circulatory failure; 2. stabilization of hemodynamics; 3. development of basic maintenance therapy; 4. differential diagnosis with carditis. 5. improvement of cardiac activity according to clinical and instrumental (ECG, X-ray, EchoCG) criteria. Duration of treatment
  5. Hypertrophic Cardiomyopathy
    It is known that patients with hypertrophic cardiomyopathy have a very high probability of fainting and sudden death. Holter monitoring is used as a tool to assess the frequency and severity of ventricular arrhythmias in this group of patients. According to Magop et al. [52], 66% (out of 99) of the patients examined or patients had ventricular “high gradation” rhythm disturbances,
  6. VT for hypertrophic cardiomyopathy
    In the literature, there are various data on the frequency of VT in patients with hypertrophic cardiomyopathy: from 17.4% [Suyama A. et al., 1986] to 44.6% [Neri R. et al., 1987]. W. Mc- Kenna, A. Kleinebenne (1985) observed 135 episodes of VT in 30 out of 100 patients. The duration of ECG recording averaged 6 days (from 1 to 15 days). The attacks were unstable: from 3 to 27 complexes (on average, 8), the frequency
  7. Hypertrophic Cardiomyopathy
    Hypertrophic cardiomyopathy (HCM) is characterized by massive ventricular hypertrophy (mostly left) and severe impairment of diastolic function. Hypertrophy of the left ventricular wall of more than 15 mm of unknown origin is considered a diagnostic criterion for hcmp. There are obstructive (narrowing the output part of the left ventricle) and non-obstructive hcmp. Hypertrophy may be symmetrical
  8. Treatment of hypertrophic cardiomyopathy
    The main objectives of the treatment of hcmp are: - providing symptomatic improvement and prolonging the life of patients by correcting the leading pathophysiological mechanisms of cardiohemodynamic impairment; - reducing the severity of pathological myocardial hypertrophy as the main morphological substrate of the hcmp or, at least, preventing its further growth; - treatment and
  9. HYPERTROPHIC CARDIOMYOPATHY
    - Primary myocardial disease of unknown etiology, manifested by asymmetric hypertrophy of the left ventricle myocardium in the absence of dilation of its cavity and causes of cardiac muscle hypertrophy. The age of patients ranges from 1 to 70 years, averaging 42 years. Among patients with hcmp predominantly males, the ratio of men and women is approximately 2: 1.
  10. Hypertrophic Cardiomyopathy
    Hypertrophic
  11. HYPERTROPHIC CARDIOMYOPATHY
    The definition of HCM is a primary myocardial damage due to the genetic inferiority of contractile proteins, characterized by LVH in the absence of a cardiac or systemic cause. Epidemiology Widely distributed among many racial groups in Europe, the USA, Canada, Israel, South America and the Far East. In the general population, its prevalence is 0.2% and is observed
  12. Hypertrophic Cardiomyopathy
    DETERMINATION of the hcmp is characterized by hypertrophy of the left or right ventricle with diffuse or segmental thickening of their walls and interventricular septum. At the same time, the cavity of the left ventricle is normal or reduced. This condition may be accompanied by a violation of the systolic or diastolic function of the ventricles. SCREENING Considering the fact that, in a significant part of cases, HCMU has
  13. Diagnosis of hypertrophic cardiomyopathy
    New methods of research that have appeared in cardiology in recent years, such as the Doppler study of the heart, magnetic resonance and positron emission tomography, have greatly expanded the possibilities of diagnosing HCM and evaluating the pathophysiological changes in this disease in clinical practice, which is important for optimizing treatment . Thanks to the success in decoding
  14. Diagnostic criteria for hypertrophic cardiomyopathy
    Since there are no strictly specific diagnostic signs of HCM, except for genetic ones, this diagnosis can be established only with a greater or lesser degree of probability. Currently, in clinical practice, it is based on the identification of left and rarely right ventricular myocardial hypertrophy, which cannot be explained by the presence of other cardiac or systemic diseases and
  15. Pathophysiological mechanisms of hypertrophic cardiomyopathy
    The main pathophysiological mechanisms of hcmp, mainly due to left ventricular hypertrophy and determining the course of the disease, include: 1. Changes in the systolic function of the left ventricle; 2. The formation of a dynamic pressure gradient in the cavity of the left ventricle; 3. Violations of the diastolic properties of the left ventricle; 4. Myocardial ischemia; 5. Changes
  16. Pathological anatomy of hypertrophic cardiomyopathy
    A macroscopic examination of the heart draws attention to significant left ventricular myocardial hypertrophy in the absence of morphological signs of congenital and acquired heart defects, ischemic heart disease, systemic arterial hypertension and other diseases that can cause the development of such hypertrophy. The thickness of the left ventricle is often 35-45 mm (V. Maron, 1993). Have
Medical portal "MedguideBook" © 2014-2016
info@medicine-guidebook.com